Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0832 | 35.1351351351 | 0.2368 | 0.34 | 0.2202 | 1351000 | 0.28080668 | CS |
4 | -0.005 | -1.53846153846 | 0.325 | 0.34 | 0.2202 | 1100875 | 0.27354406 | CS |
12 | -1.41 | -81.5028901734 | 1.73 | 1.96 | 0.2202 | 2821067 | 0.39662469 | CS |
26 | -0.95 | -74.8031496063 | 1.27 | 1.97 | 0.2202 | 1655270 | 0.62019119 | CS |
52 | -10.48 | -97.037037037 | 10.8 | 11.26 | 0.2202 | 1483092 | 1.67413368 | CS |
156 | -11.98 | -97.3983739837 | 12.3 | 13.15 | 0.2202 | 815230 | 3.95886926 | CS |
260 | -2.05 | -86.4978902954 | 2.37 | 20.04 | 0.2202 | 1054794 | 4.2259037 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約